Vertex Pharmaceuticals reported strong commercial and pipeline momentum at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, highlighting a combined $500 million revenue target for 2025 from CASGEVY and JOURNAVX and a $5 billion peak sales potential across its Crinetics portfolio.
The company, which generated $12.59 billion in trailing-twelve-month revenue and carries a market capitalization of $131.27 billion, posted 10.23% revenue growth and trades at a P/E ratio of 30.15, according to InvestingPro data. Its stock was tracking at $516.34 during the conference, up 0.60%.
JOURNAVX, Vertex’s non-opioid acute pain treatment, reached 1.6 million prescriptions in 2025. The addressable U.S. acute pain market represents approximately 80 million annual prescriptions, and reimbursement access covered 260 million lives as of early August 2025. Vertex expects scripts to grow roughly threefold in 2026 from the 2025 base, according to Executive Vice President Jasper van Grunsven, who leads the pain franchise.
In the cystic fibrosis space, next-generation program VX-828 is expected to deliver first-look data before year-end 2025. The AMPLITUDE phase III study is set to complete full enrollment this year, with interim data anticipated in early 2027. A companion AMPLIFIED phase II trial targeting patients with two APOL1 alleles will involve roughly 50 participants.
Povetacicept, being developed for IgA nephropathy, demonstrated a 52% reduction in urinary protein-to-creatinine ratio (UPCR) at 36 weeks in clinical testing. The therapy, delivered via a monthly auto-injector at a 0.46 mL dose, has a PDUFA date of November 30, 2025. Vertex estimates more than 130,000 biopsy-confirmed IgAN patients in the U.S.
Inaxaplin, an APOL1-mediated kidney disease asset, showed a 47.6% UPCR reduction over 13 weeks in phase II data. The condition progresses at roughly twice the rate of traditional kidney disease, according to Vertex. Proof-of-concept readouts for inaxaplin are also expected before year-end.
Other milestones ahead include proof-of-concept data for the myotonic dystrophy type 1 program and full-year accounting information to be discussed on the Q3 earnings call. Diabetic peripheral neuropathy studies — one enrolling approximately 1,100 patients and a second 700 — are expected to yield data in mid-2027. Myasthenia gravis phase II testing will involve about 30 patients.
The Crinetics acquisition, which brought PALSONIFY and atumelnant into Vertex’s pipeline, is projected to reach $5 billion in peak sales. Commercial leadership for the portfolio remains under Chief Commercial Officer Duncan McKechnie, while celebrity spokespersons Lindsey Vonn and Jayson Tatum continue to represent JOURNAVX in marketing efforts.
Cantor Fitzgerald’s Carter Gould moderated the session, with Vertex investor relations staff Susie Lisa and Manisha Pai participating in the discussion.
